Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
One option will certainly be Novartis, who have already shown their interest in Fap.
Novartis Innovative Therapies AG has agreed to make an upfront payment of $50 million for Clovis’s clinical candidate, FAP-2286, and could pay an additional $333.75 million if certain development milestones are reached, plus $297 million for subsequent sales goals.
Novartis’s offer could be scuttled by a higher bid—should any materialize....
https://www.google.com/amp/s/www.wsj.com/amp/articles/clovis-enters-bankruptcy-with-deal-to-sell-cancer-drug-candidate-to-novartis-11670871930
In addition, Novartis Head of partnering and licencing is watching Avacta and has publicly 'liked' via linkedin Avacta AVA6k progress (ODD news)
Would be good to use this thread to discuss potential partners and try to avoid engagement with trolls.
Concerning AVA6K and pre|CISION, Avacta had options to partner / licence during the pre clinical stage. They also had options to licence / partner on TMAC ('significant commercial interest').
Avacta chose to go phase1a alone (carrying all risk) as success (achieving proof of concept in the clinical setting) moves the needle with regards to the value Avacta can command via licence or partner.
Importantly, according to AS, the data from phase1a is unequivocal, which means Avacta really is in a strong position to command great terms.
Optionality is important.
Make no mistake, there is already a bidding war underway for this tech.
Eventually (perhaps by today) the sell side volume will be completely finished.
Assuming the majority of shares are held by those researched enough to understand what is now 'market' value of preCISION (and TMAC), there wont be many shares available for sale until much much higher valuations.
I would also love for this to drop back to sub 100p (what an opportunity that was)
The only people speaking negatively now are those looking to get a lower entry. The future for Avacta has never been more clear than it is now.
How much cash does Point have?
While Takeda, Novartis, Astra, Roche, Gilead et al are all viable candidates, POINT I think could be the dark horse.
If AS is really keen to retain AVA6k (and it is not simply a negotiating tactic to drive best value,) one way to do so would be strategic partnership with PNT and raise via NASDAQ.
It is now an incredible opportunity. Yes, should Avacta operate as a standalone, they would still have some way to go to fully commercialize but the prize here is now most certainly a takeover or major partnership deal